title: A promising new approach of VEGFR2-based DNA vaccine for tumor immunotherapy.
abstract: OBJECTIVE
  To develop new approach for tumor immunotherapy with VEGFR2-based DNA vaccine.
  
  
  METHODS
  VEGFR2 derived from different species were prepared by RT-PCR and subjected to recombinant constructs. The chimeric gene of VEGFR2 was prepared by integrating different epitopes in different species. By transfecting into cells, the immunological effect was evaluated with the approaches of ELISA, ELISPOT, and animal experiments.
  
  
  RESULTS
  (1) All these constructs, in particular chimeric construct, can result in both humoral- and cellular-immune response in BALB/c mice after immunization evaluated by the ratio of CD4+/CD8+ and release of IFN-gamma and IL-4 respectively. (2) Mice were vaccinated with these constructs and challenged with renal carcinoma cells subsequently. It manifested that tumor growth was suppressed significantly in the mice vaccinated by chimeric VEGFR2 construct.
  
  
  CONCLUSIONS
  Our results manifested that VEGFR2-based DNA chimeric vaccine could be developed as a promising approach for tumor immunotherapy.
authors: Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
authors: Jinqi
authors: J
authors: Yan
authors: Rui
authors: R
authors: Jia
authors: Hongbin
authors: H
authors: Song
authors: Ying
authors: Y
authors: Liu
authors: Liang
authors: L
authors: Zhang
authors: Wei
authors: W
authors: Zhang
authors: Yu
authors: Y
authors: Wang
authors: Yunfeng
authors: Y
authors: Zhu
authors: Jiyun
authors: J
authors: Yu
mesh_terms: D000818:Animals; D015153:Blotting, Western; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection; D047368:Tumor Burden / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics / Q000276:immunology* / Q000378:metabolism
chemical_list: D019496:Cancer Vaccines; D019444:Vaccines, DNA; D040301:Vascular Endothelial Growth Factor Receptor-2